^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Astrocytoma

    Related cancers:
    5d
    Ivosidenib and Vorasidenib decrease intratumoral 2-hydroxyglutarate and total choline levels in patients with lower-grade glioma: an in vivo MR Spectroscopy study. (PubMed, Clin Cancer Res)
    The striking reductions in tumor 2HG and tCho levels early following initiation of targeted therapy using an IDH inhibitor suggest that MRS may provide an important tool for monitoring treatment response of lower-grade gliomas.
    Preclinical • Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    Tibsovo (ivosidenib) • Voranigo (vorasidenib)
    6d
    A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma (clinicaltrials.gov)
    P1, N=24, Recruiting, University of Nebraska | Trial completion date: Mar 2027 --> Jul 2029 | Trial primary completion date: Mar 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    temozolomide • abexinostat (CG-781)
    8d
    Features of brain involvement in tuberous sclerosis patients in the Republic of Bashkortostan (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova)
    Raising awareness of TS among physicians in all specialties is essential to ensure comprehensive case reporting. Genetic confirmation of TS enables effective treatment with mTOR inhibitors. All TS patients should consult a psychiatrist and psychologist for the diagnosis and management of intellectual disability, autism spectrum disorders, and behavioral disorders.
    Retrospective data • Journal
    |
    TSC2 (TSC complex subunit 2) • TSC1 (TSC complex subunit 1)
    10d
    Gasdermin as a Molecular Signature and Predictor of Adult-Type Diffuse Glioma Severity and Grading. (PubMed, J Clin Med)
    GSDMD is significantly associated with astrocytoma severity, tumor size, and inflammatory status, with elevated expression indicating a worse prognosis. Its correlation with tumor grade, survival and high specificity in distinguishing patients from healthy individuals, underlines its promise as a clinically relevant, non-sex-specific biomarker for diagnosis and monitoring.
    Journal
    |
    CRP (C-reactive protein) • GSDMD (Gasdermin D)
    10d
    Pediatric Pleomorphic Xanthoastrocytomas: A Multicenter Neuroradiological and Clinical Correlation Study. (PubMed, AJNR Am J Neuroradiol)
    Pediatric PXAs exhibit distinct neuroimaging and molecular features correlating with prognosis. Integrated evaluation of radiological and clinical features is critical to improve risk stratification and guide personalized therapeutic strategies in this rare tumor population.
    Journal
    |
    BRAF (B-raf proto-oncogene) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    BRAF V600E • BRAF V600 • CDKN2A deletion
    10d
    Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA (clinicaltrials.gov)
    P2, N=37, Recruiting, Northwell Health | Trial completion date: May 2027 --> May 2036 | Trial primary completion date: May 2026 --> May 2035
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    Erbitux (cetuximab)
    11d
    Microsurgical Resection of Subependymal Giant Cell Astrocytoma: Single-Center Retrospective Analysis and Meta-Analysis. (PubMed, Neurosurgery)
    Microsurgical resection of SEGA is a safe and effective therapeutic option, particularly in patients without hydrocephalus. Early surgical intervention may reduce the need for VPS and long-term complications, offering a valid alternative or complement to mechanistic target of rapamycin inhibitor therapy, with durable tumor control especially in unilateral cases.
    Retrospective data • Journal
    |
    mTOR (Mechanistic target of rapamycin kinase)
    |
    sirolimus
    11d
    Predicting Clinical Prognosis and Treatment Response in Glioblastoma Based on Gene Replication Stress-Related Features. (PubMed, Curr Med Chem)
    We constructed and verified a four-gene ORS-based prognosis model for GBM, linking replication stress to immune evasion and drug sensitivity for the first time. Experimental validation confirmed the pro-tumorigenic role of PDCL3, offering potential biomarkers and therapeutic targets.
    Journal • IO biomarker
    |
    NXPH4 (Neurexophilin 4)
    |
    Xalkori (crizotinib) • vinorelbine tartrate
    13d
    Seizure-presenting IDH-wildtype glioblastoma and the upregulation of a synaptic signature. (PubMed, J Neurosurg)
    In IDH-wildtype GBM, tumors presenting with seizures had smaller volumes than those presenting with other signs. Transcriptionally, seizure presentation in IDH-wildtype GBM correlated with the upregulation of synaptic and ionic pathways, with SLC17A8 holding independent predictive value for seizure presentation.
    Journal
    |
    CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • IGF1 (Insulin-like growth factor 1) • ADAMTS2 (ADAM Metallopeptidase With Thrombospondin Type 1 Motif 2)
    |
    IDH wild-type
    15d
    Role of Surrogate Immunohistochemistry Markers in CNS Tumors in the Era of Molecular Diagnostics With Recent Updates. (PubMed, Adv Anat Pathol)
    The review emphasizes that when interpreted alongside histomorphology and conventional markers, surrogate immunohistochemistry can significantly reduce reliance on molecular testing, expedite diagnosis, and improve accessibility of precision diagnostics. Standardization, validation, and awareness of pitfalls remain essential to maximizing their clinical utility in neuropathology practice.
    Journal
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • ATRX (ATRX Chromatin Remodeler) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • BCOR (BCL6 Corepressor) • YAP1 (Yes associated protein 1) • VIM (Vimentin) • STAT6 (Signal transducer and activator of transcription 6) • L1CAM (L1 cell adhesion molecule) • DUX4 (Double Homeobox 4) • FOXR2 (Forkhead Box R2) • GAB1 (GRB2 Associated Binding Protein 1)
    |
    TP53 mutation • BRAF V600E • BRAF V600 • IDH mutation + BRAF V600E
    15d
    Genomic Alteration Patterns Across Histological Grades in BRAF p.V600E-Mutant Gliomas and Glioneuronal Tumors: An Analysis of 15 Cases. (PubMed, Pathol Int)
    These findings indicate substantial genomic heterogeneity among BRAF p.V600E-mutant gliomas and glioneuronal tumors. While low-grade tumors are generally genomically quiet, a subset shows increased alterations, and high-grade tumors tend to acquire copy-number changes, highlighting the limitations of genomic event counts alone as a surrogate for malignant potential.
    Journal
    |
    BRAF (B-raf proto-oncogene) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    BRAF V600E • BRAF V600 • CDKN2A deletion